Aneb.Pk
Aneb provides healthcare diagnostic services, focusing on laboratory testing and related medical research.
Business. Aneb provides healthcare diagnostic services, focusing on laboratory testing and related medical research.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Aneb provides healthcare diagnostic services, focusing on laboratory testing and related medical research.
Aneb operates with a highly liquid capital structure, as evidenced by a current ratio of 24.53, indicating strong short-term liquidity. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative approach to leverage. However, the company's operating cash flow is negative at -6.35 million USD, reflecting ongoing operational challenges.
Profitability metrics show significant underperformance relative to industry norms. Aneb reported a net loss of 8.48 million USD and an operating loss of 9.22 million USD, resulting in a return on equity of -72.78% and a return on assets of -69.86%. These figures indicate a company that is not generating returns for shareholders or effectively utilizing its assets.
The company's geographic and segment exposure is not disclosed in the available data, but the absence of segment-specific financials suggests a lack of diversification or a single business line. Given the negative operating and net income, it is likely that the company's revenue is concentrated in a limited number of services or geographic areas.
Aneb's growth trajectory is currently negative, with no disclosed revenue and a loss per share of -0.25 USD. The company has not provided forward-looking guidance, and there are no indications of a near-term turnaround in the financial data. The absence of analyst revenue estimates further complicates the assessment of future performance.
Risk factors for Aneb include the lack of profitability and negative cash flow, which could lead to liquidity constraints if the company is unable to secure additional financing. The risk assessment indicates low dilution potential, but the company's financial position remains precarious. No immediate filing-based liquidity or dilution flags were detected, but the company's financial health is a concern.
Recent events and filings do not provide additional insight into Aneb's operations or strategic direction. The company's financial statements show a consistent pattern of losses, and there are no recent transcripts or filings that suggest a change in strategy or operational improvement.
- Aneb has a highly liquid balance sheet with a current ratio of 24.53 and no long-term debt.
- The company is unprofitable, with a return on equity of -72.78% and a return on assets of -69.86%.
- Aneb's financial position is characterized by negative operating and net income, indicating operational challenges.
- The company's growth trajectory is negative, with no disclosed revenue and a loss per share of -0.25 USD.
- Risk factors include the lack of profitability and negative cash flow, which could lead to liquidity constraints.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- ANEB.PK Market data — financials · 2026-05-27
- Anebulo Pharmaceuticals Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): -40.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -47.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -39.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 69.1%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.19xDerived (calculated)
- Current assets (annual): USD 9.27MSEC XBRL filing
- Total assets (annual): USD 9.42MSEC XBRL filing
- Shares outstanding (annual): 41.08MSEC XBRL filing
- Total liabilities (annual): USD 1.49MSEC XBRL filing
- Cash & equivalents (annual): USD 9.04MSEC XBRL filing
- Shareholders' equity (annual): USD 7.94MSEC XBRL filing
- Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): 21.5%Derived (calculated)
- Operating income (YoY) (2025-06-30 vs 2024-06-30): -11.0%Derived (calculated)
- R&D expense (YoY) (2025-06-30 vs 2024-06-30): 21.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 21.9%Derived (calculated)
- Net income (YoY) (2025-06-30 vs 2024-06-30): -3.5%Derived (calculated)
- EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 21.9%Derived (calculated)
- Net income (annual): USD -8.48MSEC XBRL filing
- Operating cash flow (annual): USD -6.35MSEC XBRL filing
- Operating income (annual): USD -9.22MSEC XBRL filing
- R&D expense (annual): USD 4.3MSEC XBRL filing
- Interest expense (annual): USD 400KSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing